Sanofi

Sanofi-synthelabo

Sanofi-aventis

Cll Pharma

Thierry Breul

Alain Bayol

Philippe Faure

Claude Aleman

Patrice Dupin

Claude Laruelle

Michel Bedos

Colette Bouloumie

Stephen Byard

Isabel Ribeiro Dos Santos

Frédérique Bourriague-Seve

Laurence Colliere

Marielle Bonnel

Philippe Bastard

The present invention relates to a solid pharmaceutical composition comprising a solid dispersion containing at least one active principle and a pharmaceutically acceptable polymer matrix,

Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose

The invention relates to non hemolytic compositions containing an antiplatelet agent such as clopidogrel or ticlopidine; these compositions being characterized in that the antiplatelet agent is in the form of free base, and the composition contains at least one hydrophilic non ionic surfactant. The invention relates also a galenic form, a method of preparation of thereof, as well as therapeutic uses of thereof, especially in patients who suffer from undesirable effects related to hemolysis and/or gastrointestinal acidity.

Oral composition containing an antiplatelet agent of the thienopyridine family in the form of free base

A subject-matter of the invention is a pharmaceutical composition for parenteral administration, characterized in that it comprises: dronedarone or one of its pharmaceutically acceptable salts as active principle; a physiologically acceptable buffer solution capable of maintaining the pH of the composition between 3 and 5; a physiologically acceptable water-soluble &#x3b2;-cyclodextrin derivative.

Pharmaceutical dronedarone composition for parenteral administration

The subject of the invention is a freeze-dried formulation consisting of an amorphous phase and a crystalline phase, which is pharmaceutically acceptable, comprising at least one nonprotein active ingredient, characterized in that it contains mannitol and alanine in a ratio R of between 0.1 and 1, R representing the mass of mannitol to the mass of alanine.

Stable freeze-dried pharmaceutical formulation

The present invention relates to an aqueous solution containing 1-&lsqb;2-(2-naphthyl)ethyl&rsqb;-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine hydrochloride (hydrochloride of SR 57746), also comprising &bgr;-cyclodextrin (&bgr;-CD) and a pharmaceutically acceptable acid or buffer to give a pH of less than or equal to 3.

Pharmaceutical composition for oral administration

The invention relates to a physically stable, pharmaceutically acceptable liquid composition containing urate oxidase, and from 0.1 mg/ml to 10 mg/ml of Poloxamer 188, in buffered aqueous medium. This composition can be obtained by dissolving a lyophilibate in an aqueous solvent.

Stable liquid composition containing urate oxidase and lyophilized

A stable, freeze-dried, and pharmaceutically acceptable formulation includes a protein, a buffer, alanine, and mannitol, at a mass ratio of mannitol/alanine being 0.1-1, wherein the formulation being useful in an assay kit.

Growing community of inventors

Montpellier, France

Thierry Breul